oxybutynin has been researched along with Parkinsonian Disorders in 2 studies
oxybutynin: RN given refers to parent cpd
oxybutynin : A racemate comprising equimolar amounts of (R)-oxybutynin and esoxybutynin. An antispasmodic used for the treatment of overactive bladder.
Parkinsonian Disorders: A group of disorders which feature impaired motor control characterized by bradykinesia, MUSCLE RIGIDITY; TREMOR; and postural instability. Parkinsonian diseases are generally divided into primary parkinsonism (see PARKINSON DISEASE), secondary parkinsonism (see PARKINSON DISEASE, SECONDARY) and inherited forms. These conditions are associated with dysfunction of dopaminergic or closely related motor integration neuronal pathways in the BASAL GANGLIA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Rasagiline mesylate is used as first line agent for early management of Parkinson's disease but its water soluble nature creates hurdles to cross blood brain barrier also its low oral bioavailability and rapid elimination requires frequent dosing." | 1.56 | Impact of rasagiline nanoparticles on brain targeting efficiency via gellan gum based transdermal patch: A nanotheranostic perspective for Parkinsonism. ( Bali, NR; Salve, PS, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bali, NR | 1 |
| Salve, PS | 1 |
| Moretti, DV | 1 |
| Binetti, G | 1 |
| Zanetti, O | 1 |
| Frisoni, GB | 1 |
1 trial available for oxybutynin and Parkinsonian Disorders
| Article | Year |
|---|---|
Non-ergot dopamine agonist rotigotine as a promising therapeutic tool in atypical parkinsonism syndromes: a 24 months pilot observational open-label study.
Topics: Administration, Cutaneous; Aged; Antiparkinson Agents; Dopamine Agonists; Follow-Up Studies; Humans; | 2014 |
1 other study available for oxybutynin and Parkinsonian Disorders
| Article | Year |
|---|---|
Impact of rasagiline nanoparticles on brain targeting efficiency via gellan gum based transdermal patch: A nanotheranostic perspective for Parkinsonism.
Topics: Administration, Cutaneous; Administration, Oral; Animals; Behavior, Animal; Brain; Catalepsy; Diffus | 2020 |